drugset / Trial / NCT04308785

A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

NCT04308785

Phase 2 Terminated 24 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multicenter, double-blind, placebo-controlled, randomized, phase II study to investigate the efficacy and safety of Atezolizumab with or without Tiragolumab as consolidation therapy in participants with limited stage small cell lung cancer who have not progressed during/after chemoradiotherapy.

Timeline

Start
2021-12-01
Primary completion
2023-07-25
Completion
2023-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous
Subject Tiragolumab Monoclonal antibody 600 mg Intravenous